MK-6204 / Merck (MSD), Sichuan Kelun Pharma - LARVOL DELTA

SKB518, SKB535/MK-6204 and SKB445: (PRNewswire) - "Novel ADC drugs with potential FIC targets. The Phase 2 clinical trial for SKB518 and the Phase 1 clinical trials for SKB535 and SKB445 are ongoing in China. The Company has entered into a license and collaboration agreement with MSD to develop SKB535."

Licensing / partnership • Trial status • Solid Tumor

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor

Sichuan Kelun Pharmaceutical Co., Ltd. Announcement on the Approval of the Clinical Trial Application of its Subsidiary SKB535 New Drug by the National Medical Products Administration [Google translation] (Sina Corp) - "Sichuan Kelun Pharmaceutical Co., Ltd...recently learned that Sichuan Kelun Botai Biopharmaceutical Co., Ltd...has received a clinical trial notification from the Drug Review Center of the National Medical Products Administration (NMPA) on November 15, 2024, approving the application for clinical trial of the innovative drug SKB535 developed by it."

New trial • Oncology